183 related articles for article (PubMed ID: 30925535)
1. HIV-1 phylogenetics and vaccines.
Rolland M
Curr Opin HIV AIDS; 2019 May; 14(3):227-232. PubMed ID: 30925535
[TBL] [Abstract][Full Text] [Related]
2. Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention.
Stephenson KE; Wagh K; Korber B; Barouch DH
Annu Rev Immunol; 2020 Apr; 38():673-703. PubMed ID: 32340576
[TBL] [Abstract][Full Text] [Related]
3. Current views on the potential for development of a HIV vaccine.
Cohen KW; Frahm N
Expert Opin Biol Ther; 2017 Mar; 17(3):295-303. PubMed ID: 28095712
[TBL] [Abstract][Full Text] [Related]
4. Prospects for a globally effective HIV-1 vaccine.
Excler JL; Robb ML; Kim JH
Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
[TBL] [Abstract][Full Text] [Related]
5. Catch Me If You Can--The Race Between HIV and Neutralizing Antibodies.
Geiß Y; Dietrich U
AIDS Rev; 2015; 17(2):107-13. PubMed ID: 26035168
[TBL] [Abstract][Full Text] [Related]
6. Tiny steps towards an HIV vaccine.
Willyard C
Nature; 2010 Jul; 466(7304):S8. PubMed ID: 20631706
[No Abstract] [Full Text] [Related]
7. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
Ahmed Y; Tian M; Gao Y
AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
[TBL] [Abstract][Full Text] [Related]
8. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
[TBL] [Abstract][Full Text] [Related]
9. Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination.
Martinez DR; Permar SR; Fouda GG
Clin Vaccine Immunol; 2016 Feb; 23(2):84-94. PubMed ID: 26656117
[TBL] [Abstract][Full Text] [Related]
10. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
11. Lessons learned from human HIV vaccine trials.
Pollara J; Easterhoff D; Fouda GG
Curr Opin HIV AIDS; 2017 May; 12(3):216-221. PubMed ID: 28230655
[TBL] [Abstract][Full Text] [Related]
12. A critical question for HIV vaccine development: which antibodies to induce?
Zolla-Pazner S
Science; 2014 Jul; 345(6193):167-8. PubMed ID: 25013066
[TBL] [Abstract][Full Text] [Related]
13. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers.
Landais E; Moore PL
Retrovirology; 2018 Sep; 15(1):61. PubMed ID: 30185183
[TBL] [Abstract][Full Text] [Related]
14. HIV Vaccines: One Step Closer.
Low MSY; Tarlinton D
Trends Mol Med; 2017 Jan; 23(1):1-3. PubMed ID: 27889424
[TBL] [Abstract][Full Text] [Related]
15. Correlations between HIV-1 clades and HIV-1 antibody neutralization sensitivity: significant for vaccine development?
van Gils MJ; Schuitemaker H
Curr HIV Res; 2010 Dec; 8(8):579-86. PubMed ID: 21054254
[TBL] [Abstract][Full Text] [Related]
16. Correlates of broadly neutralizing antibody development.
Abela IA; Kadelka C; Trkola A
Curr Opin HIV AIDS; 2019 Jul; 14(4):279-285. PubMed ID: 31107283
[TBL] [Abstract][Full Text] [Related]
17. Rhesus Macaque B-Cell Responses to an HIV-1 Trimer Vaccine Revealed by Unbiased Longitudinal Repertoire Analysis.
Dai K; He L; Khan SN; O'Dell S; McKee K; Tran K; Li Y; Sundling C; Morris CD; Mascola JR; Karlsson Hedestam GB; Wyatt RT; Zhu J
mBio; 2015 Nov; 6(6):e01375-15. PubMed ID: 26530382
[TBL] [Abstract][Full Text] [Related]
18. Systems serology for decoding infection and vaccine-induced antibody responses to HIV-1.
Pittala S; Morrison KS; Ackerman ME
Curr Opin HIV AIDS; 2019 Jul; 14(4):253-264. PubMed ID: 31033729
[TBL] [Abstract][Full Text] [Related]
19. Virological features associated with the development of broadly neutralizing antibodies to HIV-1.
Moore PL; Williamson C; Morris L
Trends Microbiol; 2015 Apr; 23(4):204-11. PubMed ID: 25572881
[TBL] [Abstract][Full Text] [Related]
20. Role of nonneutralizing antibodies in vaccines and/or HIV infected individuals.
Mayr L; Su B; Moog C
Curr Opin HIV AIDS; 2017 May; 12(3):209-215. PubMed ID: 28422785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
